Positron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such Settings.

[1]  David T. Jones,et al.  FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD , 2021, NeuroImage: Clinical.

[2]  Yiyun Huang,et al.  PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research , 2021, Frontiers in Aging Neuroscience.

[3]  C. Rowe,et al.  Early detection of amyloid load using 18F-florbetaben PET , 2021, Alzheimer's research & therapy.

[4]  A. Evans,et al.  Effect of Alzheimer's Disease and Lewy Body Disease on Metabolic Changes. , 2021, Journal of Alzheimer's disease : JAD.

[5]  Young Ho Park,et al.  Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment , 2021, Alzheimer's Research & Therapy.

[6]  David T. Jones,et al.  Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019 , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[7]  T. Werner,et al.  Amyloid Hypothesis: The Emperor's New Clothes? , 2020, Journal of Alzheimer's disease : JAD.

[8]  B. Miller,et al.  Longitudinal structural and metabolic changes in frontotemporal dementia , 2020, Neurology.

[9]  David T. Jones,et al.  β-Amyloid PET and neuropathology in dementia with Lewy bodies , 2019, Neurology.

[10]  Jungsu S. Oh,et al.  Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer’s disease differ according to disease severity and amyloid positivity , 2019, PloS one.

[11]  M. Yun,et al.  Distinguishing between dementia with Lewy bodies and Alzheimer's disease using metabolic patterns , 2019, Neurobiology of Aging.

[12]  G. Rücker,et al.  Predictive Value of 18F-Florbetapir and 18F-FDG PET for Conversion from Mild Cognitive Impairment to Alzheimer Dementia , 2019, The Journal of Nuclear Medicine.

[13]  W. Jagust,et al.  18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes , 2019, Alzheimer's Research & Therapy.

[14]  W. M. van der Flier,et al.  Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project , 2018, JAMA neurology.

[15]  C. Jack,et al.  Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting , 2018, JAMA neurology.

[16]  F Nobili,et al.  European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus , 2018, European journal of neurology.

[17]  G. Frisoni,et al.  Clinical utility of FDG-PET for the clinical diagnosis in MCI , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Leon Flicker,et al.  18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). , 2017, The Cochrane database of systematic reviews.

[19]  S. Bisdas,et al.  The diagnostic value of FDG and amyloid PET in Alzheimer's disease-A systematic review. , 2017, European journal of radiology.

[20]  E. Croteau,et al.  A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease , 2017, Experimental Gerontology.

[21]  A. Fleisher,et al.  Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease , 2017, Alzheimer's & dementia.

[22]  D. Guilloteau,et al.  β-amyloid PET neuroimaging: A review of radiopharmaceutical development , 2017 .

[23]  A. Hammers,et al.  Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  D. J. Brooks,et al.  Tau imaging in neurodegenerative diseases , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  D. Perani,et al.  Right Limbic FDG-PET Hypometabolism Correlates with Emotion Recognition and Attribution in Probable Behavioral Variant of Frontotemporal Dementia Patients , 2015, PloS one.

[26]  J. Hornberger,et al.  Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective. , 2015, The journal of mental health policy and economics.

[27]  S. Pal,et al.  A systematic review and meta-analysis of 18F-labeled amyloid imaging in Alzheimer's disease , 2015, Alzheimer's & dementia.

[28]  S. Rollinson,et al.  Patterns of microglial cell activation in frontotemporal lobar degeneration , 2014, Neuropathology and applied neurobiology.

[29]  Kazuhiko Yanai,et al.  Tau PET Imaging in Alzheimer’s Disease , 2014, Current Neurology and Neuroscience Reports.

[30]  Keith A. Johnson,et al.  Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altropane positron emission tomography study , 2014, Alzheimer's Research & Therapy.

[31]  Kazuhiko Yanai,et al.  Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. , 2014, Brain : a journal of neurology.

[32]  H. Zaidi,et al.  Regions of Interest–Based Discriminant Analysis of DaTSCAN SPECT and FDG-PET for the Classification of Dementia , 2013, Clinical nuclear medicine.

[33]  A. Alavi,et al.  Amyloid-β imaging with PET in Alzheimer’s disease: is it feasible with current radiotracers and technologies? , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[35]  S. Gilman,et al.  Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. , 2011, Brain : a journal of neurology.

[36]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[37]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[38]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[39]  Johannes C. Klein,et al.  Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo , 2010, Neurology.

[40]  B. Långström,et al.  The use of PET in Alzheimer disease , 2010, Nature Reviews Neurology.

[41]  W. Jagust,et al.  Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo , 2009, Behavioural neurology.

[42]  C. Rowe,et al.  The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-β-CIT SPECT for Diagnosis of Dementia with Lewy Bodies , 2009, Journal of Nuclear Medicine.

[43]  T. Suhara,et al.  Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET , 2009, Neuroscience Research.

[44]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[45]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[46]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[47]  B. Långstrom,et al.  A Positron Emission Tomography Study to Assess Binding of Lecozotan, a Novel 5‐Hydroxytryptamine‐1A Silent Antagonist, to Brain 5‐HT1A Receptors in Healthy Young and Elderly Subjects, and in Patients With Alzheimer's Disease , 2008, Clinical pharmacology and therapeutics.

[48]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[49]  Uwe Haberkorn,et al.  Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease , 2007, Psychiatry Research: Neuroimaging.

[50]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[51]  Jennifer Farmer,et al.  Frontotemporal dementia: Clinicopathological correlations , 2006, Annals of neurology.

[52]  P. Scheltens,et al.  Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer’s Disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[53]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[54]  Elizabeth L Sampson,et al.  In vivo detection of microglial activation in frontotemporal dementia , 2004, Annals of neurology.

[55]  A. Drzezga,et al.  Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study , 2004, Neurobiology of Aging.

[56]  A. Drzezga,et al.  Region-Specific Decline of Cerebral Glucose Metabolism in Patients with Frontotemporal Dementia: A Prospective 18F-FDG-PET Study , 2004, Dementia and Geriatric Cognitive Disorders.

[57]  A. Alavi,et al.  A Metabolic Imaging Severity Rating Scale for the Assessment of Cognitive Impairment , 2003, Clinical nuclear medicine.

[58]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[59]  J. Baron,et al.  The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration. , 2002, Brain : a journal of neurology.

[60]  R. Koeppe,et al.  Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex , 2000, Annals of neurology.

[61]  K. Ishii,et al.  Cerebral glucose metabolism in patients with frontotemporal dementia. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[62]  G. Alexander,et al.  Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease , 1998, Neurology.

[63]  R. Frackowiak,et al.  Chromosome 14 linked familial Alzheimer's disease. A clinico-pathological study of a single pedigree. , 1995, Brain : a journal of neurology.

[64]  A. Alavi,et al.  Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  K. Herholz,et al.  Activation PET as an Instrument to Determine Therapeutic Efficacy in Alzheimer's Disease a , 1993, Annals of the New York Academy of Sciences.

[66]  M J de Leon,et al.  Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. , 1992, Archives of neurology.

[67]  Richard S. J. Frackowiak,et al.  The use of positron emission tomography in the clinical assessment of dementia. , 1992, Seminars in nuclear medicine.

[68]  D. Sullivan,et al.  Positron emission tomography in neuropsychiatry. , 1991, Investigative radiology.

[69]  M. Weiner,et al.  Single photon tomography in Alzheimer's disease and the dementias. , 1990, Seminars in nuclear medicine.

[70]  D. Selkoe,et al.  Clinically diagnosed Alzheimer's disease: Autopsy results in 150 cases , 1988, Annals of neurology.

[71]  W. Jagust,et al.  Longitudinal studies of regional cerebral metabolism in Alzheimer's disease , 1988, Neurology.

[72]  W. Snow,et al.  The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease , 1988, Neurology.

[73]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[74]  David T. Jones,et al.  F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies , 2020 .

[75]  E. Liu,et al.  A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease. , 2016, The journal of prevention of Alzheimer's disease.

[76]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.

[77]  A. Forsberg,et al.  Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. , 2011, Journal of Alzheimer's disease : JAD.

[78]  Shan Baoci.  PET and fMRI to evaluate the results of acupuncture treatment of the cognition of Alzheimer’s disease , 2004 .

[79]  J C Froment,et al.  Positron Emission Tomography Metabolic Data Corrected for Cortical Atrophy Using Magnetic Resonance Imaging , 1996, Alzheimer disease and associated disorders.

[80]  J V Haxby,et al.  High-resolution PET studies in Alzheimer's disease. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[81]  B Horwitz,et al.  Abnormal brain glucose metabolism in Alzheimer's disease, as measured by position emission tomography. , 1991, Advances in experimental medicine and biology.

[82]  G. Fink,et al.  Positron emission tomography in the differential diagnosis of organic dementias. , 1991, Journal of neural transmission. Supplementum.